Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020-June 2021.
COVID-19
Japan
SARS
SARS-CoV-2
contact tracing
coronavirus
coronavirus disease
epidemiology
household contact
respiratory infections
severe acute respiratory syndrome coronavirus 2
viral genome
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
17
6
2022
medline:
23
7
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
Household transmission is a primary source of SARS-CoV-2 spread. We used COVID-19 epidemiologic investigation data and viral genome analysis data collected in the city of Kyoto, Japan, during January 2020-June 2021 to evaluate the effects of different settings and viral strains on SARS-CoV-2 transmission. Epidemiologic investigations of 5,061 COVID-19 cases found that the most common category for close contact was within households (35.3%); this category also had the highest reverse transcription PCR positivity. The prevalent viral lineage shifted from B.1.1.214 in the third wave to the Alpha variant in the fourth wave. The proportion of secondary cases associated with households also increased from the third to fourth waves (27% vs. 29%). Among 564 contacts from 206 households, Alpha variant was significantly associated with household transmission (odds ratio 1.52, 95% CI 1.06-2.18) compared with B.1.1.214. Public health interventions targeting household contacts and specific variants could help control SARS-CoV-2 transmission.
Identifiants
pubmed: 35710464
doi: 10.3201/eid2808.220420
pmc: PMC9328921
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
JAMA Pediatr. 2021 Nov 1;175(11):1151-1158
pubmed: 34398179
mSphere. 2020 Nov 11;5(6):
pubmed: 33177213
Nature. 2021 Apr;592(7852):122-127
pubmed: 33636719
Emerg Infect Dis. 2021 Dec;27(12):3009-3019
pubmed: 34695369
Int J Infect Dis. 2020 Jul;96:503-505
pubmed: 32416146
Clin Infect Dis. 2020 Nov 5;71(8):1953-1959
pubmed: 32382743
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Infect Genet Evol. 2021 Oct;94:105013
pubmed: 34352360
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Lancet Infect Dis. 2021 May;21(5):617-628
pubmed: 33476567
Jpn J Infect Dis. 2020 Nov 24;73(6):491-493
pubmed: 32611985
Lancet Reg Health Eur. 2022 Jan;12:100252
pubmed: 34729548
JAMA Netw Open. 2021 Aug 2;4(8):e2122240
pubmed: 34448865
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
JAMA Netw Open. 2021 Jun 1;4(6):e2115850
pubmed: 34081135
Euro Surveill. 2021 Jul;26(27):
pubmed: 34240695
Nat Med. 2021 Sep;27(9):1518-1524
pubmed: 34504335
Clin Microbiol Infect. 2021 Jan 30;:
pubmed: 33524589
Int J Infect Dis. 2020 Oct;99:374-380
pubmed: 32768702
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32521222
Int J Epidemiol. 2021 Nov 10;50(5):1444-1457
pubmed: 34151970